-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

Benzinga·11/06/2026 14:28:41
Listen to the news
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neutral and raises the price target from $8 to $12.